About Phase Genomics
Phase Genomics is a company based in Seattle (United States) founded in 2015. Phase Genomics has raised $5.75 million across 19 funding rounds from investors including NIH, Gates Foundation and HHS. Phase Genomics offers products and services including CytoTerra Platform, ProxiMeta Platform, and Proximo Platform. Phase Genomics operates in a competitive market with competitors including Candel Therapeutics, StrideBio, Tessera Therapeutics, Genedit and Genenta Science, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Phase Genomics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.75 M (USD)
in 19 rounds
-
Latest Funding Round
$1.5 M (USD), Grant
Mar 05, 2024
-
Investors
NIH
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Phase Genomics
Phase Genomics offers a comprehensive portfolio of products and services, including CytoTerra Platform, ProxiMeta Platform, and Proximo Platform.
Tool for cytogenetics analysis and chromosomal abnormality detection
Platform for metagenome deconvolution and microbial host attribution
System for ultra-long-range genome mapping and analysis
People of Phase Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Phase Genomics
Phase Genomics has successfully raised a total of $5.75M across 19 strategic funding rounds. The most recent funding activity was a Grant round of $1.5 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Phase Genomics
Phase Genomics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Climate tech investing and support for early-stage entrepreneurs in North America.
|
Locked | Locked | Locked | |
|
Early-stage investments are made in Washington-based startups by WRF Capital.
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for Phase Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Phase Genomics
Investment portfolio details for Phase Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Phase Genomics
Detailed financials for Phase Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Phase Genomics Comparisons
Peer comparison for Phase Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Phase Genomics
Phase Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Candel Therapeutics, StrideBio, Tessera Therapeutics, Genedit and Genenta Science, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
|
| Locked | Locked | Locked |
New genome engineering technology is provided for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| Locked | Locked | Locked |
Lentivirus-based gene and cell therapies for cancer are developed.
|
Detailed competitors of Phase Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Phase Genomics
Complete news archive for Phase Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phase Genomics
Phase Genomics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Phase Genomics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Phase Genomics is a funded company, having raised a total of $5.75M across 19 funding rounds to date.
Provider of laboratory and computational services and products. The company has developed technology that allows the extraction of information regarding the physical proximity of DNA stretches inside the nucleus from short- or long-read HT sequencing allowing researchers to reconstruct the 3D organization of DNA within the nucleus. Phase Genomics Proximo Hi-C measures the proximity of DNA in vivo and uses that information to scaffold contigs into entire chromosomes, or to deconvolute metagenomes from complex mixtures of environmental DNA.
Phase Genomics's top competitors include Tessera Therapeutics, Genenta Science and Genedit.
Phase Genomics offers CytoTerra Platform, ProxiMeta Platform, and Proximo Platform.
Phase Genomics has 9 investors. Key investors include NIH, Gates Foundation, HHS, National Cancer Institute, and NHGRI.